Clinical Trial Update: A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC). [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating R1507 plus Erlotinib in non-squamous non-small cell lung cancer; trial terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Non-squamous Non-small Cell Lung Cancer

Drugs mentioned

• R1507
• Tarceva (erlotinib)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Non-Squamous Non-Small Cell Lung Cancer | Phase 2 | Status: TERMINATED | Results posted: 2021-01-05